Century Therapeutics (IPSC) Accumulated Expenses (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Accumulated Expenses data on file, last reported at $8.5 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 187.94% year-over-year to $8.5 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 187.94% increase from a year earlier, with the FY2025 full-year figure at $11.7 million, down 33.13% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $8.5 million, down from $11.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for IPSC reached as high as $17.5 million in Q4 2024 and fell as low as $721000.0 in Q3 2022.
• Historically, Accumulated Expenses has averaged $7.9 million across 5 years, with a median of $7.2 million in 2022.
• Across the five-year window, Accumulated Expenses plunged 90.07% in 2022 and jumped 1277.53% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $7.1 million in 2022, then retreated by 8.01% to $6.5 million in 2023, then soared by 168.8% to $17.5 million in 2024, then slumped by 33.13% to $11.7 million in 2025, then declined by 27.4% to $8.5 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $8.5 million in Q1 2026, $11.7 million in Q4 2025, and $11.1 million in Q3 2025.